奥浦迈14.5亿元并购案再遭独董反对

Core Viewpoint - The company is currently not in a position to pursue acquisitions, as indicated by the independent director's repeated opposition to the proposed acquisition of Pengli Bio [1][2] Group 1: Acquisition Details - The company plans to acquire 100% of Pengli Bio for approximately 1.45 billion yuan, with an estimated valuation of 1.452 billion yuan by the end of 2024, reflecting a 56.62% increase in value [1] - The independent director has expressed concerns about the necessity of the acquisition, stating that the company does not require it at this stage [1] Group 2: Financial Performance - In the first three quarters of the year, the company reported revenue of approximately 272 million yuan, representing a year-on-year growth of 25.79%, and a net profit of about 49.43 million yuan, up 81.48% year-on-year [2] - Following the acquisition, the company expects to recognize goodwill of 555 million yuan, which would account for 849.41% of the projected net profit for 2024 [2] Group 3: Industry Context - The CRO industry is characterized by intense competition and significant market segmentation, with a rising risk of price wars due to stringent cost control from downstream clients [2] - The company faces potential risks related to the target company's performance, including the possibility of goodwill impairment if the acquired company's operational results are poor [2]